Organization Overview
Historical Acquisition Tree
Alternative names
Key: Horizon Therapeutics, LLC (5) Acquired (1)
glycerol phenylbutyrate (ravicti) (2013)
inebilizumab (Uplizna) (2020 NDA)
interferon gamma-1b (actimmune) (1999 NDA)
pegloticase (krystexxa) (2010)
sodium phenylbutyrate (buphenyl) (1996)
teprotumumab (Tepezza) (2020 NDA)
Key: Horizon Therapeutics, LLC (5) Acquired (1)
Key: Horizon Therapeutics, LLC (2) Acquired (2)
Disease (Phase 4)
Eye Diseases (Phase 4)
Gout (Phase 4)
Graves Ophthalmopathy (Phase 4)
Scleroderma, Diffuse (Phase 1)
Scleroderma, Systemic (Phase 1)
Sclerosis (Phase 1)
Thyroid Diseases (Phase 4)
Urea Cycle Disorders, Inborn (Phase 4)